转移性激素敏感性前列腺癌诊断和治疗的最新进展

Recent advances in diagnosis and treatment of metastatic hormone-sensitive prostate cancers

转移性激素敏感性前列腺癌(metastatic hormone-sensitive prostate cancer,mHSPC)是指已经发生转移的晚期前列腺癌中较常见的一种类型,因此对于mHSPC诊断和治疗的研究具有较高的价值。近期对mHSPC的诊疗研究主要着重于利用mHSPC的生物学特征进行靶向追踪诊断及雄激素剥夺治疗(androgen deprivation therapy,ADT)、紫杉烷类药物化疗、新型雄激素受体靶向剂、放射治疗、免疫治疗等。多项研究表明针对mHSPC的分子检测技术的提高可以对患者的诊断及预后的判断提供较大的帮助。在mHSPC的众多化疗药物中,阿比特龙加强的松的治疗效果较优。另外如阿帕鲁胺这类新型雄激素受体靶向剂已经被证实可以提高安全性,进而提高患者的生存质量。针对不同mHSPC患者采用相应的联合疗法进行个体化治疗将有效地改善预后。未来还需研发不良反应更低的mHSPC化疗药物。

Metastatic hormone-sensitive prostate cancer(mHSPC) is a common type of advanced prostate cancers that has metastasized. Therefore, the research on the diagnosis and treatment of mHSPC is of high value. Recent studies on the diagnosis and treatment of mHSPC mainly focus on the use of biological characteristics of m HSPC for targeted tracking diagnosis and androgen deprivation therapy(ADT), taxane-based chemohormonal therapy, new androgen receptor targeting agent, radiotherapy, immunotherapy, etc. A number of studies have shown that the improvement of molecular detection technology for mHSPC can provide great help for the diagnosis and prognosis of patients. Among many chemotherapeutic drugs of mHSPC, abiraterone plus prednisone have a better therapeutic effect. In addition, new androgen receptor targeting agent such as apalutamide have been proved to improve safety and improve the quality of patients’ life. Individualized treatment with corresponding combination therapy for different m HSPC patients will improve the prognosis effectively. In the future, m HSPC chemotherapy drugs with lower adverse reactions need to be developed.